Jefferies Financial Group Inc. Apellis Pharmaceuticals, Inc. Call Options Transaction History

Jefferies Financial Group Inc.

5 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q1 2024 May 13, 2024	BUY	$55.39 - $72.47 $2.98 Million - $3.9 Million	53,800 Added 1681.25%	57,000 $3.35 Million
Q4 2023 Feb 13, 2024	BUY	$37.14 - $64.82 $115,134 - $200,941	3,100 Added 3100.0%	3,200 $191,000
Q3 2023 Nov 14, 2023	SELL	$23.65 - $89.22 $972,014 - $3.67 Million	-41,100 Reduced 99.76%	100 $3,000
Q2 2023 Aug 14, 2023	BUY	$76.68 - $93.31 $1.89 Million - $2.3 Million	24,700 Added 149.7%	41,200 $3.75 Million
Q1 2023 May 15, 2023	BUY	$46.59 - $66.96 $768,735 - $1.1 Million	16,500 New	16,500 $1.09 Million

308

115M

3.85M

1.09M

Ticker APLS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 109,865,000
Market Cap $3.64B
Description
Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for...

Get notified when there are updates to the investment portfolio of Jefferies Financial Group Inc., based on Form 13F filings with the SEC.

Stay updated on Jefferies Financial Group Inc. with notifications on news.